TRPV2 and breast carcinoma: There was a study that reported that LL-37 binds to ErbB2 receptor and transient receptor potential cation (TRPV2) which led to activation of MAPK signaling and the PI3K/AKT pathway in breast cancer cells and resulted in enhanced cell proliferation, migration, and anchorage-independent growth [53,54,55,56].